ArticleCancer research2021
PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer.
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- MOF promotes venous thromboembolism in lung cancer by activating the YBX1-MALT1-NF-κB-PAI-1 axis, possibly through histone crotonylation.The Journal of biological chemistry · 2026Article
- Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer.bioRxiv : the preprint server for biology · 2026Article
- Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer.Science advances · 2026Review
- The Role of Four New Biochemical Markers in the Diagnosis and Prognosis of Ovarian Carcinoma.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- PAX Family, Master Regulator in Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models.The Journal of clinical investigation · 2025Article
- A Comprehensive Analysis of the Role of PAX9 in Head and Neck Squamous Cell Carcinoma.Current molecular medicine · 2025Article
- Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets.MedComm · 2024Review
- Article
- Onco-Ontogeny of Squamous Cell Cancer of the First Pharyngeal Arch Derivatives.International journal of molecular sciences · 2024Review
- Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.Nature reviews. Clinical oncology · 2024Review
- A SWI/SNF-dependent transcriptional regulation mediated by POU2AF2/C11orf53 at enhancer.Nature communications · 2024Article
- Lineage-specific intolerance to oncogenic drivers restricts histological transformation.Science (New York, N.Y.) · 2024Article
- Novel Therapeutic Options for Small Cell Lung Cancer.Current oncology reports · 2023Review
- Analyses of Transcriptomics Cell Signalling for Pre-Screening Applications in the Integrated Approach for Testing and Assessment of Non-Genotoxic Carcinogens.International journal of molecular sciences · 2022Review
- POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity.Science advances · 2022Article
- MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.Genome biology · 2022Article
- PAX9 in Cancer Development.International journal of molecular sciences · 2022Review
- Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.Oncogene · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Abnormalities in genetic and epigenetic modifications can lead to drastic changes in gene expression profiles that are associated with various cancer types. Small cell lung cancer (SCLC) is an aggressive and deadly form of lung cancer with limited effective therapies currently available. By utilizing a genome-wide CRISPR-Cas9 dropout screen in SCLC cells, we identified paired box protein 9 (PAX9) as an essential factor that is overexpressed in human malignant SCLC tumor samples and is transcriptionally driven by the BAP1/ASXL3/BRD4 epigenetic axis. Genome-wide studies revealed that PAX9 occupies distal enhancer elements and represses gene expression by restricting enhancer activity. In multiple SCLC cell lines, genetic depletion of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.